



PA (UYDU-) UNIV DUKE.  
 XX Kornbluth SA, Holley C;  
 XX WPI: 2002-241769/29.  
 DR N-PSDB; AAD31598.  
 XX  
 PT New human homologue of Drosophila melanogaster reaper protein (hrpr),  
 PT useful for generating antibodies and for screening compounds, which can  
 PT inhibit or enhance hrpr activity -  
 XX  
 PS Claim 1; Fig 1; 45pp; English.  
 XX  
 CC The invention relates to human homologue of Drosophila melanogaster  
 CC Reaper protein (hrpr) and its corresponding nucleic acid. The hrpr  
 CC polypeptides are useful for generating antibodies, which can be used  
 CC in detection or purification protocols designed to detect or purify  
 CC the polypeptide to which the antibody is directed. These sequences  
 CC are also used for screening compounds, which can enhance or inhibit  
 CC hrpr and for treating tumours. The hrpr polynucleotides are useful  
 CC as a probe or primer. The present sequence is human homologue of  
 CC Drosophila melanogaster reaper protein (hrpr).  
 CC  
 SQ Sequence 81 AA:  
 Query Match 100.0%; Score 81; DB 23; Length 81;  
 Best Local Similarity 100.0%; Pred. No. 3.2e-77;  
 Matches 81; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 MLSTHFLYFLYFLYSYSGDRAKCLRTKQKQKQQLROSEVLFRESETLRTKTKG 60  
 DB 1 MLSTHFLYFLYFLYSYSGDRAKCLRTKQKQKQQLROSEVLFRESETLRTKTKG 60  
 QY 61 RRMGGGCGRGCTADTGSMFLS 81  
 DB 61 RRMGGGCGRGCTADTGSMFLS 81  
 Db 61 RRMGGGCGRGCTADTGSMFLS 81  
 RESULT 2  
 AAE19842  
 ID AAE19842 standard; peptide: 20 AA.  
 XX  
 AC AAE19842;  
 XX  
 DT 18-JUN-2002 (first entry)  
 XX  
 DE Human hrpr derived peptide.  
 XX  
 KW Human: reaper protein; Rpr; detection; purification; screening;  
 KW therapy; tumour; cytostatic.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200212540-A2.  
 PD 14-FEB-2002.  
 XX  
 PE 08-AUG-2001; 2001WO-US24765.  
 XX  
 PR 08-AUG-2000; 2000US-223699P.  
 XX  
 PA (UYDU-) UNIV DUKE.  
 XX  
 PI Kornbluth SA, Holley C;  
 XX  
 DR WPI: 2002-241769/29.  
 XX  
 PT New human homologue of Drosophila melanogaster reaper protein (hrpr),  
 PT useful for generating antibodies and for screening compounds, which can  
 PT inhibit or enhance hrpr activity -  
 XX  
 PS Example 1; Page 19; 45pp; English.

CC The invention relates to human homologue of Drosophila melanogaster  
 CC Reaper protein (hrpr) and its corresponding nucleic acid. The hrpr  
 CC polypeptides are useful for generating antibodies, which can be used  
 CC in detection or purification protocols designed to detect or purify  
 CC the polypeptide to which the antibody is directed. These sequences  
 CC are also used for screening compounds, which can enhance or inhibit  
 CC hrpr and for treating tumours. The hrpr polynucleotides are useful  
 CC as a probe or primer. The present sequence is human homologue of  
 CC Drosophila melanogaster reaper protein (hrpr) derived peptide.  
 CC  
 SQ Sequence 20 AA:  
 Query Match 21.0%; Score 17; DB 23; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 1.3e-10;  
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 39 QILROSEVLFRESETLRK 55  
 DB 4 QILROSEVLFRESETLRK 20  
 RESULT 3  
 AAG02507  
 ID AAG02507 standard; Protein: 71 AA.  
 XX  
 AC AAG02507;  
 XX  
 DT 06-OCT-2000 (first entry)  
 XX  
 DE Human secreted protein, SEQ ID NO: 6588.  
 XX  
 KW Human; 5' EST; expressed sequence tag; secreted protein; cDNA isolation;  
 KW gene therapy; chromosome mapping.  
 XX  
 OS Homo sapiens.  
 XX  
 PN EP1033401-A2.  
 PD 06-SEP-2000. *Not out*  
 XX  
 PE 21-FEB-2000; 2000EP-0200610.  
 XX  
 PR 26-FEB-1999; 99US-0122487.  
 XX  
 PA (GEST) GENSET.  
 XX  
 PI Dumas Milne Edwards J, Duclert A, Giordano J;  
 XX  
 DR WPI: 2000-500381/45.  
 DR N-PSDB; AAC02513.  
 XX  
 PT New nucleic acid that is a 5' expressed sequence tag (5' EST) for  
 PT obtaining cDNAs and genomic DNAs that correspond to 5'ESTs and for  
 PT diagnostic, forensic, gene therapy and chromosome mapping procedures -  
 XX  
 PS Claim 13; SEQ ID 6588; 71pp + CD-ROM; English.  
 XX  
 CC The present sequence is a polypeptide encoded by one of a large number  
 CC of 5' ESTs derived from mRNAs encoding secreted proteins. The 5' ESTs  
 CC were prepared from total human RNAs or polyA+ RNAs derived from 30  
 CC different tissues. EST sequences usually correspond mainly to the 3'  
 CC untranslated region (UTR) of the mRNA because they are often obtained  
 CC from oligo-dT primed cDNA libraries. Such ESTs are not well suited for  
 CC isolating cDNA sequences derived from the 5' ends of mRNAs and even in  
 CC those cases where longer cDNA sequences have been obtained, the full 5'  
 CC UTR is rarely included. 5' ESTs are derived from mRNAs with intact 5'  
 CC ends and can therefore be used to obtain full length cDNAs and genomic  
 CC DNAs. 5' ESTs are also used in diagnostic, forensic, gene therapy and  
 CC chromosome mapping procedures. They are used to obtain upstream  
 CC regulatory sequences and to design expression and secretion vectors.  
 CC  
 SQ Sequence 71 AA;

Query Match 13.6%; Score 11; DB 21; Length 71;  
Best Local Similarity 100.0%; Pred. No. 0.00073;  
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 7 LFIYLFIFPLS 17  
Db 14 LFIYLFIFPLS 24

RESULT 4

AA002957 standard; Protein: 117 AA.  
AA002957:  
06-NOV-2001 (first entry)  
Human polypeptide SEQ ID NO 16849.

Human; cytokine; cell proliferation; cell differentiation; gene therapy;  
tissue growth factor; immunomodulatory; cancer; leukaemia;  
nervous system disorders; arthritis; inflammation.

Homo sapiens.

WO200164835-A2.

07-SEP-2001.

26-FEB-2001; 2001WO-US04927.

28-FEB-2000; 2000US-0515126.

18-MAY-2000; 2000US-0577409.

(HYSE-) HYSEQ INC.

Tang YT, Liu C, Drmanac RT;

WPI; 2001-514838/56.

N-PSDB; AA162886.

Isolated nucleic acids and polypeptides, useful for preventing  
diagnosing and treating e.g. leukaemia, inflammation and immune  
disorders -

Claim 20; SEQ ID NO 16849; 1399pp + Sequence Listing; English.

The invention relates to human polynucleotides (AA179941-AA193841) and  
the encoded proteins (AA000010-AA013910) that exhibit activity relating to  
cytokine, cell proliferation or cell differentiation or which may induce  
production of other cytokines in other cell populations. The  
polynucleotides and polypeptides are useful in gene therapy, vaccines or  
peptide therapy. The polypeptides have various cytokine-like activities,  
e.g. stem cell growth factor activity, haematopoiesis regulating  
activity, tissue growth factor activity, immunomodulatory activity and  
activin/inhibin activity and may be useful in the diagnosis and/or  
treatment of cancer, leukaemia, nervous system disorders, arthritis and  
inflammation.  
Note: The sequence data for this patent did not form part of the printed  
specification, but was obtained in electronic format directly from WIPO  
at [ftp.wipo.int/pub/published\\_pcl\\_sequences](http://wipo.int/pub/published_pcl_sequences).

Sequence 117 AA;

Query Match 12.3%; Score 10; DB 22; Length 117;

Best Local Similarity 100.0%; Pred. No. 0.013;

Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 19 SLGDRARICL 28

Db 15 SLGDRARICL 24

RESULT 5

AAU29487 standard; Protein: 181 AA.

AAU29487:

18-DEC-2001 (first entry)

Human G protein-coupled receptor (GPCR) polypeptide #108.

Human; G protein-coupled receptor; GPCR; mental disorder; schizophrenia;  
neurological disorder; metabolic disorder; cancer; rheumatoid arthritis;  
thyroid disorder; neurodegenerative disorder; cardiovascular disorder;  
renal failure; autoimmune disorder; hyperproliferative disorder; HIV;  
human immunodeficiency virus; viral infection; neuroprotective;  
immunostimulant; neuroleptic; nootropic; tranquiliser; antidepressant;  
anorectic; gene therapy.

Homo sapiens.

WO200168658-A2.

20-SEP-2001.

16-MAR-2001; 2001WO-US08456.

16-MAR-2000; 2000US-187783P.

16-MAR-2000; 2000US-189907P.

16-MAR-2000; 2000US-189917P.

16-MAR-2000; 2000US-189918P.

16-MAR-2000; 2000US-189960P.

29-MAR-2000; 2000US-192155P.

29-MAR-2000; 2000US-192234P.

29-MAR-2000; 2000US-192830P.

29-MAR-2000; 2000US-192916P.

29-MAR-2000; 2000US-192923P.

29-MAR-2000; 2000US-192933P.

29-MAR-2000; 2000US-192945P.

(PHAA) PHARMACIA & UPJOHN CO.

Vogel I G;

WPI; 2001-607458/69.

N-PSDB; AAS46926.

Nucleic acid encoding G protein-coupled receptors, useful for the  
prevention, diagnosis and treatment of mental disorders -

Claim 31; Page 94; 274pp; English.  
Sequences AAU29380-AAU29509 represent human G protein-coupled receptor  
(GPCR) polypeptides of the invention. The proteins and the DNA sequences  
encoding them can be used to identify compounds which bind to GPCR  
polypeptides and in screening for compounds that modulate GPCR activity.  
By screening a human subject for the presence of mutations in GPCR DNA, a  
GPCR-related disorder or a genetic predisposition can be diagnosed. The  
sequences can also be used for treatment and prevention of mental  
disorders such as schizophrenia, neurological disorders such as manic  
depression, metabolic disorders such as obesity, cancer, rheumatoid  
arthritis, thyroid disorders such as myxoedema, neurodegenerative  
disorders such as Parkinson's disease, cardiovascular disorders such as  
atherosclerosis, renal failure, autoimmune disorders, hyperproliferative  
disorders such as psoriasis and viral infections such as those caused by  
HIV.

Sequence 181 AA;

Query Match 12.3%; Score 10; DB 22; Length 181;

Best Local Similarity 100.0%; Pred. No. 0.018;

Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 19 SLGDRARLCL 28  
 DB 1 SLGDRARLCL 10  
 RESULT 6  
 ABB60775  
 ID ABB60775 standard; Protein; 181 AA.  
 XX  
 XX ABB60775;  
 XX  
 DT 13-AUG-2002 (first entry)  
 XX  
 DE Novel G protein coupled receptor (ngPCR-x) #108.  
 XX  
 KW G protein coupled receptor; ngPCR-x; immune response; thyroid disorder;  
 KW mental disorder; thyrotoxicosis; myxedema; inflammatory condition;  
 KW Crohn's disease; cell differentiation; homeostasis; rheumatoid arthritis;  
 KW renal failure; autoimmune disorder; movement disorder; CNS disorder;  
 KW viral infection; human immunodeficiency virus; HTV; metabolic disorder;  
 KW cardiovascular disorder; diabetes; obesity; anorexia; cardiomyopathy;  
 KW proliferative disease; cancer; psoriasis; lung cancer; hormonal disorder;  
 KW sexual dysfunction.  
 XX  
 OS Homo sapiens.  
 PN US2002058306-A1.  
 XX  
 PD 16-MAY-2002.  
 XX  
 PF 16-MAR-2001; 2001US-0811284.  
 XX  
 PR 16-MAR-2000; 2000US-189783P.  
 PR 16-MAR-2000; 2000US-189907P.  
 PR 16-MAR-2000; 2000US-189917P.  
 PR 16-MAR-2000; 2000US-189918P.  
 PR 16-MAR-2000; 2000US-189960P.  
 PR 24-MAR-2000; 2000US-192153P.  
 PR 27-MAR-2000; 2000US-192233P.  
 PR 29-MAR-2000; 2000US-192830P.  
 PR 29-MAR-2000; 2000US-192945P.  
 PR 29-MAR-2000; 2000US-192916P.  
 PR 29-MAR-2000; 2000US-192923P.  
 PR 29-MAR-2000; 2000US-192830P.  
 PR 29-MAR-2000; 2000US-192945P.  
 PR 29-MAR-2000; 2000US-192830P.  
 PR 29-MAR-2000; 2000US-192945P.  
 PR 29-MAR-2000; 2000US-192830P.  
 PR 29-MAR-2000; 2000US-192945P.  
 PA (VOGE/) VOGELI G.  
 XX  
 XX VogelI G;  
 PI  
 XX  
 DR WPI: 2002-434856/46.  
 DR N-PSDB; ABB61704.  
 XX  
 XX  
 PT New isolated nucleic acid encoding a G protein coupled receptor for  
 PT producing the receptor which can induce an immune response in a mammal  
 PT  
 XX  
 PS Claim 27; Page 72; 216pp; English.  
 XX  
 CC The invention describes an isolated nucleic acid (I) comprising a  
 CC sequence encoding a portion of a G protein coupled receptor (ngPCR-x).  
 CC (I) is used to produce a recombinant ngPCR-x polypeptide. A polypeptide  
 CC encoded by (I) is used to induce an immune response in a mammal. ngPCR-x  
 CC is used to identify a compound that binds to it and/or modulates it's  
 CC activity. (I) is used to identify animal homologues of ngPCR-x. (I) can  
 CC be used to diagnose a human subject as having a brain or genetic  
 CC predisposition disorder, such as a mental disorder. (I) is used to  
 CC screen for an ngPCR-x related disorder including thyroid disorders (e.g.  
 CC thyrotoxicosis, myxedema), renal failure, inflammatory conditions (e.g.

CC Crohn's disease), diseases related to cell differentiation and  
 CC homeostasis, rheumatoid arthritis, autoimmune disorders, movement  
 CC disorders, CNS disorders, viral infections (e.g. diabetes, obesity,  
 CC virus), metabolic and cardiovascular disorders (e.g. diabetes, obesity,  
 CC anorexia, cardiomyopathies), proliferative diseases and cancers (e.g.  
 CC psoriasis, lung cancer), hormonal disorders, sexual dysfunction and  
 CC hereditary mental disorders in a human patient. A host cell comprising  
 CC (I) is used to screen for a modulator of ngPCR-x activity. ngPCR-x is  
 CC used to identify compounds that can treat mental disorders. The  
 CC polypeptide encoded by (I) is used to purify a G protein from a sample.  
 CC This is the amino acid sequence of a novel G protein coupled receptor  
 CC (ngPCR-x) protein described in the invention.  
 XX  
 SQ Sequence 181 AA;  
 XX  
 QY 19 SLGDRARLCL 28  
 DB 1 SLGDRARLCL 10  
 RESULT 7  
 AAB34577  
 ID AAB34577 standard; Protein; 29 AA.  
 XX  
 XX AAB34577;  
 AC  
 DT 26-JAN-2001 (first entry)  
 XX  
 DE Human secreted protein sequence encoded by gene 1 SEQ ID NO:61.  
 XX  
 KW Human; secreted protein; diagnosis; immunosuppressive; antiarthritic;  
 KW antirheumatic; antiproliferative; cytostatic; cardiant; vasotropic;  
 KW cerebroprotective; neuroprotective; antidiabetic; vitruclide;  
 KW fungicide; ophthalmological; gene therapy; autoimmune disease; neoplasm;  
 KW hyperproliferative disorder; cancer; cardiovascular disorder; infection;  
 KW cerebrovascular disorder; angiogenesis; nervous system disorder;  
 KW ocular disorder; wound healing; skin aging; food additive; preservative.  
 XX  
 OS Homo sapiens.  
 PN WO200056751-A1.  
 XX  
 PD 28-SEP-2000.  
 XX  
 PF 09-MAR-2000; 2000MO-US06013.  
 XX  
 PR 19-MAR-1999; 99US-0125360.  
 PR 11-JUN-1999; 99US-0138626.  
 PR 03-DEC-1999; 99US-0168662.  
 XX  
 PA (HUMA-) HUMAN GENOME SCI INC.  
 XX  
 XX Rosen CA, Ruben SM, Komatsoulis G;  
 PI  
 XX  
 DR WPI: 2000-579482/54.  
 DR N-PSDB; AAC59738.  
 XX  
 XX  
 PT Isolated nucleic acid molecule encoding a human secreted protein is  
 PT used in preventing, treating or ameliorating a medical condition  
 PT  
 XX  
 PS Claim 11; Page 371; 419pp; English.  
 XX  
 CC The polynucleotide sequences given in AAC59738 to AAC59787 encode the  
 CC human secreted proteins given in AAB34577 to AAB34626. AAB34627 to  
 CC AAB34686 represent human secreted polypeptide sequences and proteins  
 CC homologous to them, which are given in the exemplification of the present  
 CC invention. Human secreted proteins have activities based on the tissues  
 CC and cells the genes are expressed in. Example of activities include:  
 CC antiarthritic; immunosuppressive; antirheumatic; antiproliferative;

CC cytosolic; cardiant; vasotropic; cerebroprotective; nootropic;  
CC neuroprotective; antibacterial; virucide; fungicide; and  
CC ophthalmological. The polynucleotides and proteins can be used to  
CC prevent, treat or ameliorate a medical condition in e.g. humans, mice,  
CC rabbits, goats, horses, cats, dogs, chickens or sheep. They are also  
CC used in diagnosing a pathological condition or susceptibility to a  
CC pathological condition. Disorders which are diagnosed or treated include  
CC autoimmune diseases, hyperproliferative disorders e.g. neoplasms and  
CC cancers of the breast or liver, cardiovascular disorders,  
CC cerebrovascular disorders, angiogenesis, nervous system disorders,  
CC infections caused by bacteria, viruses and fungi and ocular disorders.  
CC The proteins can also be used to aid wound healing and epithelial cell  
CC proliferation, to prevent skin aging due to sunburn, to maintain organs  
CC before transplantation, for supporting cell culture of primary tissues,  
CC to regenerate tissues and in chemotaxis. The proteins can also be used  
CC as a food additive or preservative to increase or decrease storage  
CC capabilities. AAC59729 to AAC59737 and AAB34576 represent sequences used  
CC in the exemplification of the present invention.

XX Sequence 29 AA;

SO

Query Match 11.18; Score 9; DB 21; Length 29;  
Best Local Similarity 100.0%; Pred. No. 0.043;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 7 LFTYLFYF 15  
| | | | | | | | | |

Db 18 LFTYLFYF 26

RESULT 8

AAM85158  
ID AAM85158 standard; Protein: 39 AA.

XX AAM85158;

XX 07-NOV-2001 (first entry)

DE Human immune/haematopoietic antigen SEQ ID NO:12751.

XX Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;

KW cytosolic; gene therapy; vaccine; metastasis.

XX Homo sapiens.

XX NO200157182-A2.

XX 09-AUG-2001.

XX 17-JAN-2001; 2001WO-US01354.

XX 31-JAN-2000; 2000US-0179065.

XX 04-FEB-2000; 2000US-0180628.

XX 24-FEB-2000; 2000US-0184664.

XX 16-MAR-2000; 2000US-0186350.

XX 16-MAR-2000; 2000US-0189874.

XX 17-MAR-2000; 2000US-0190076.

XX 18-APR-2000; 2000US-0198123.

XX 19-MAY-2000; 2000US-0203513.

XX 07-JUN-2000; 2000US-0209467.

XX 28-JUN-2000; 2000US-0214886.

XX 30-JUN-2000; 2000US-0215135.

XX 07-JUL-2000; 2000US-0216647.

XX 07-JUL-2000; 2000US-0216880.

XX 11-JUL-2000; 2000US-0217487.

XX 11-JUL-2000; 2000US-0217496.

XX 14-JUL-2000; 2000US-0218290.

XX 26-JUL-2000; 2000US-0220963.

XX 26-JUL-2000; 2000US-0220964.

XX 14-AUG-2000; 2000US-0224518.

XX 14-AUG-2000; 2000US-0224519.

XX 14-AUG-2000; 2000US-0225213.

XX 14-AUG-2000; 2000US-0225214.

PR 14-AUG-2000; 2000US-0225266.  
PR 14-AUG-2000; 2000US-0225267.  
PR 14-AUG-2000; 2000US-0225268.  
PR 14-AUG-2000; 2000US-0225270.  
PR 14-AUG-2000; 2000US-0225447.  
PR 14-AUG-2000; 2000US-0225757.  
PR 14-AUG-2000; 2000US-0225758.  
PR 14-AUG-2000; 2000US-0225759.  
PR 14-AUG-2000; 2000US-0225759.  
PR 16-AUG-2000; 2000US-0226279.  
PR 22-AUG-2000; 2000US-0226681.  
PR 22-AUG-2000; 2000US-0226868.  
PR 22-AUG-2000; 2000US-0227182.  
PR 23-AUG-2000; 2000US-0227109.  
PR 30-AUG-2000; 2000US-0228924.  
PR 01-SEP-2000; 2000US-0229287.  
PR 01-SEP-2000; 2000US-0229343.  
PR 01-SEP-2000; 2000US-0229344.  
PR 01-SEP-2000; 2000US-0229345.  
PR 05-SEP-2000; 2000US-0229509.  
PR 05-SEP-2000; 2000US-0229513.  
PR 06-SEP-2000; 2000US-0230437.  
PR 06-SEP-2000; 2000US-0230438.  
PR 08-SEP-2000; 2000US-0231242.  
PR 08-SEP-2000; 2000US-0231243.  
PR 08-SEP-2000; 2000US-0231244.  
PR 08-SEP-2000; 2000US-0231413.  
PR 08-SEP-2000; 2000US-0231414.  
PR 08-SEP-2000; 2000US-0232080.  
PR 08-SEP-2000; 2000US-0232081.  
PR 12-SEP-2000; 2000US-0231968.  
PR 14-SEP-2000; 2000US-0232397.  
PR 14-SEP-2000; 2000US-0232398.  
PR 14-SEP-2000; 2000US-0232399.  
PR 14-SEP-2000; 2000US-0232400.  
PR 14-SEP-2000; 2000US-0232401.  
PR 14-SEP-2000; 2000US-0233063.  
PR 14-SEP-2000; 2000US-0233064.  
PR 14-SEP-2000; 2000US-0233065.  
PR 21-SEP-2000; 2000US-0234223.  
PR 21-SEP-2000; 2000US-0234274.  
PR 25-SEP-2000; 2000US-0234997.  
PR 25-SEP-2000; 2000US-0234998.  
PR 26-SEP-2000; 2000US-0235484.  
PR 27-SEP-2000; 2000US-0235834.  
PR 27-SEP-2000; 2000US-0235836.  
PR 27-SEP-2000; 2000US-0235837.  
PR 29-SEP-2000; 2000US-0236367.  
PR 29-SEP-2000; 2000US-0236367.  
PR 29-SEP-2000; 2000US-0236368.  
PR 29-SEP-2000; 2000US-0236369.  
PR 29-SEP-2000; 2000US-0236370.  
PR 02-OCT-2000; 2000US-0236802.  
PR 02-OCT-2000; 2000US-0237037.  
PR 02-OCT-2000; 2000US-0237038.  
PR 02-OCT-2000; 2000US-0237039.  
PR 02-OCT-2000; 2000US-0237040.  
PR 13-OCT-2000; 2000US-0239935.  
PR 13-OCT-2000; 2000US-0239937.  
PR 20-OCT-2000; 2000US-0240960.  
PR 20-OCT-2000; 2000US-0241221.  
PR 20-OCT-2000; 2000US-0241785.  
PR 20-OCT-2000; 2000US-0241786.  
PR 20-OCT-2000; 2000US-0241787.  
PR 20-OCT-2000; 2000US-0241808.  
PR 20-OCT-2000; 2000US-0241809.  
PR 20-OCT-2000; 2000US-0241826.  
PR 01-NOV-2000; 2000US-0244617.  
PR 01-NOV-2000; 2000US-0246475.  
PR 08-NOV-2000; 2000US-0246475.  
PR 08-NOV-2000; 2000US-0246476.  
PR 08-NOV-2000; 2000US-0246477.  
PR 08-NOV-2000; 2000US-0246478.  
PR 08-NOV-2000; 2000US-0246523.  
PR 08-NOV-2000; 2000US-0246524.

PR 08-NOV-2000; 2000US-0246525.  
PR 08-NOV-2000; 2000US-0246526.  
PR 08-NOV-2000; 2000US-0246527.  
PR 08-NOV-2000; 2000US-0246528.  
PR 08-NOV-2000; 2000US-0246529.  
PR 08-NOV-2000; 2000US-0246530.  
PR 08-NOV-2000; 2000US-0246531.  
PR 08-NOV-2000; 2000US-0246532.  
PR 08-NOV-2000; 2000US-0246533.  
PR 08-NOV-2000; 2000US-0246534.  
PR 08-NOV-2000; 2000US-0246535.  
PR 08-NOV-2000; 2000US-0246536.  
PR 08-NOV-2000; 2000US-0246537.  
PR 08-NOV-2000; 2000US-0246538.  
PR 08-NOV-2000; 2000US-0246539.  
PR 08-NOV-2000; 2000US-0246540.  
PR 08-NOV-2000; 2000US-0246541.  
PR 08-NOV-2000; 2000US-0246542.  
PR 08-NOV-2000; 2000US-0246543.  
PR 08-NOV-2000; 2000US-0246544.  
PR 08-NOV-2000; 2000US-0246545.  
PR 08-NOV-2000; 2000US-0246546.  
PR 08-NOV-2000; 2000US-0246547.  
PR 08-NOV-2000; 2000US-0246548.  
PR 08-NOV-2000; 2000US-0246549.  
PR 08-NOV-2000; 2000US-0246550.  
PR 08-NOV-2000; 2000US-0246551.  
PR 08-NOV-2000; 2000US-0246552.  
PR 08-NOV-2000; 2000US-0246553.  
PR 08-NOV-2000; 2000US-0246554.  
PR 08-NOV-2000; 2000US-0246555.  
PR 08-NOV-2000; 2000US-0246556.  
PR 08-NOV-2000; 2000US-0246557.  
PR 08-NOV-2000; 2000US-0246558.  
PR 08-NOV-2000; 2000US-0246559.  
PR 08-NOV-2000; 2000US-0246560.  
PR 08-NOV-2000; 2000US-0246561.  
PR 08-NOV-2000; 2000US-0246562.  
PR 08-NOV-2000; 2000US-0246563.  
PR 08-NOV-2000; 2000US-0246564.  
PR 08-NOV-2000; 2000US-0246565.  
PR 08-NOV-2000; 2000US-0246566.  
PR 08-NOV-2000; 2000US-0246567.  
PR 08-NOV-2000; 2000US-0246568.  
PR 08-NOV-2000; 2000US-0246569.  
PR 08-NOV-2000; 2000US-0246570.  
PR 08-NOV-2000; 2000US-0246571.  
PR 08-NOV-2000; 2000US-0246572.  
PR 08-NOV-2000; 2000US-0246573.  
PR 08-NOV-2000; 2000US-0246574.  
PR 08-NOV-2000; 2000US-0246575.  
PR 08-NOV-2000; 2000US-0246576.  
PR 08-NOV-2000; 2000US-0246577.  
PR 08-NOV-2000; 2000US-0246578.  
PR 08-NOV-2000; 2000US-0246579.  
PR 08-NOV-2000; 2000US-0246580.  
PR 08-NOV-2000; 2000US-0246581.  
PR 08-NOV-2000; 2000US-0246582.  
PR 08-NOV-2000; 2000US-0246583.  
PR 08-NOV-2000; 2000US-0246584.  
PR 08-NOV-2000; 2000US-0246585.  
PR 08-NOV-2000; 2000US-0246586.  
PR 08-NOV-2000; 2000US-0246587.  
PR 08-NOV-2000; 2000US-0246588.  
PR 08-NOV-2000; 2000US-0246589.  
PR 08-NOV-2000; 2000US-0246590.  
PR 08-NOV-2000; 2000US-0246591.  
PR 08-NOV-2000; 2000US-0246592.  
PR 08-NOV-2000; 2000US-0246593.  
PR 08-NOV-2000; 2000US-0246594.  
PR 08-NOV-2000; 2000US-0246595.  
PR 08-NOV-2000; 2000US-0246596.  
PR 08-NOV-2000; 2000US-0246597.  
PR 08-NOV-2000; 2000US-0246598.  
PR 08-NOV-2000; 2000US-0246599.  
PR 08-NOV-2000; 2000US-0246600.

(HUMA-) HUMAN GENOME SCI INC.

Rosen CA, Barash SC, Ruben SM,  
WPI: 2001-483426/52.  
N-PSDB; AAK57939.

Nucleic acids encoding human immune/hematopoietic antigen polypeptides,  
useful for preventing, diagnosing and/or treating cancers and  
metastasis -

Claim 11; SEQ ID NO 12751; 3071bp + Sequence Listing; English.

AAK54951 to AAK64702 encode the human immune/hematopoietic antigen (I)  
amino acid sequences given in AAM2170 to AAM91921. (I) have cytostratic  
activity and can be used in gene therapy and vaccine production. (I)  
proteins and polynucleotides may be used in the prevention, diagnosis and  
treatment of diseases associated with inappropriate (I) expression. For  
example, they may be used to treat disorders associated with decreased  
expression by rectifying mutations or deletions in a patient's genome  
that affect the activity of (I) by expressing inactive proteins or to  
supplement the patients own production of (I). Additionally, (I)  
polynucleotides may be used to produce the secreted (I), by inserting  
the nucleic acids into a host cell and culturing the cell to express the  
protein. (I) proteins and polynucleotides may be used to prevent,  
diagnose and treat immune/hematopoietic-related diseases, especially  
cancers and cancer metastases of hematopoietic-derived cells. AAK64703  
to AAK87994 represent human immune/hematopoietic antigen genomic  
sequences from the present invention. AAK54942 to AAK54950 and AAM82169  
represent sequences used in the exemplification of the present invention.

```

SQ      Sequence      39 AA:
Query Match      11.1%; Score 9; DB 22; Length 39;
Best Local Similarity 100.0%; Pred. No. 0.055;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0
Oy      19 SLGDRARLC 27
      |||||||
Db      26 SLGDRARLC 34

RESULT 9
AA012138
ID      AA012138 standard; Protein; 43 AA.
XX      AA012138;
AC
XX      06-NOV-2001 (first entry)
DT
XX      Human polypeptide SEQ ID NO 26030.
DE
XX      Human polypeptide SEQ ID NO 26030.
KW      Human; cytokine; cell proliferation; cell differentiation; gene therapy;
KW      vaccine; peptide therapy; stem cell growth factor; haematopoiesis;
KW      tissue growth factor; immunomodulatory; cancer; leukaemia;
KW      nervous system disorders; arthritis; inflammation.
XX      Homo sapiens.
OS      WO200164835-A2.
PN      07-SEP-2001.
PD
XX      26-FEB-2001; 2001WO-US04927.
PF
XX      28-FEB-2000; 2000US-0515126.
PR      18-MAY-2000; 2000US-0577409.
XX      (HXSE-) HXSEQ INC.
PA
XX      Tang YT, Liu C, Drmanac RT;
PI      WPI: 2001-514838/56.
DR      N-PSDB: AA192069.
XX      Isolated nucleic acids and polypeptides, useful for preventing
PT      diagnosing and treating e.g. leukaemia, inflammation and immune
PT      disorders -
XX      Claim 20; SEQ ID NO 26030; 1399pp + Sequence Listing; English.
PS
XX      The invention relates to human polynucleotides (AA179941-AA193841) and
CC      the encoded proteins (AA000010-AA013910) that exhibit activity elating to
CC      cytokine, cell proliferation or cell differentiation or which may induce
CC      production of other cytokines in other cell populations. The
CC      polynucleotides and polypeptides are useful in gene therapy, vaccines or
CC      peptide therapy. The polypeptides have various cytokine-like activities,
CC      e.g. stem cell growth factor activity, haematopoiesis regulating
CC      activity, tissue growth factor activity, immunomodulatory activity and
CC      activin/inhibin activity and may be useful in the diagnosis and/or
CC      treatment of cancer, leukaemia, nervous system disorders, arthritis and
CC      inflammation.
CC      Note: The sequence data for this patent did not form part of the printed
CC      specification, but was obtained in electronic format directly from WIPO
CC      at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ      Sequence      43 AA:
Query Match      11.1%; Score 9; DB 22; Length 43;
Best Local Similarity 100.0%; Pred. No. 0.06;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0
Oy      7 LFIVLFIYF 15
      |||||||

```

Db 3 LEIYLFIYF 11

RESULT 10

ABP10360

ID ABP10360 standard; Protein: 57 AA.

XX

AC ABP10360;

XX

DT 24-JUN-2002 (first entry)

XX

DE Human ORFX protein sequence SEQ ID NO:20702.

XX

KM Human: open reading frame; ORFX: gene therapy; cancer; cirrhosis;

KM hyperproliferative disorder; psoriasis; benign tumour; haemorrhage;

KM degenerative disorder; osteoarthritis; neurodegenerative disorder;

KM cardiovascular disease; diabetes mellitus; systemic lupus erythematosus;

KM hypertension; hypothyroidism; cholesterol ester storage disease;

KM immune deficiency; immune disorder; infectious disease;

KM autoimmune disorder; rheumatoid arthritis; autoimmune thyroiditis;

KM myasthenia gravis.

XX

OS Homo sapiens.

XX

PN WO200192523-A2.

PD

XX 06-DEC-2001.

XX

PE 29-MAY-2001; 2001WO-US10836.

XX

PR 30-MAY-2000; 2000US-206132P.

XX 29-AUG-2000; 2000US-228716P.

XX

PA (CURA-) CURAGEN CORP.

PI Shimkets RA, Leach MD;

PI WPI: 2002-106308/14.

DR N-PSDB; ABN26112.

XX

PT Novel human polypeptides and polynucleotides useful for diagnosing,

PT preventing and treating cardiovascular disease, neurodegenerative,

PT hyperproliferative disorders and autoimmune disorders

XX

PS Disclosure; SEQ ID 20702; 1037pp; English.

XX

CC The present invention describes substantially purified human proteins

CC (referred to as open reading frame, ORFX, where X is 1-11491 (see Table 1

CC in the specification). ABN15762 to ABN27252 encode the human ORFX

CC proteins given in ABP00010 to ABP11500. ORFX proteins are useful for

CC treating or preventing a pathology associated with an ORFX-associated

CC disorder in humans, and in the manufacture of a medicament for treating a

CC syndrome associated with ORFX-associated disorder. ORFX polynucleotide

CC sequences can be used in gene therapy. ORFX sequences can be used in the

CC treatment of cancer, hyperproliferative disorders, cirrhosis of liver,

CC psoriasis, benign tumours, keloid, degenerative disorders, haemorrhage,

CC osteoarthritis, neurodegenerative disorders, disorders related to organ

CC transplantation, cardiovascular diseases, diabetes mellitus, systemic

CC lupus erythematosus, hypertension, hypothyroidism, cholesterol ester

CC storage disease, various immune deficiencies and disorders, infectious

CC diseases, autoimmune disorders such as multiple sclerosis, rheumatoid

CC arthritis, autoimmune thyroiditis, myasthenia gravis, graft-versus-host

CC disease and autoimmune inflammatory eye disease. ORFX proteins are also

CC useful for treating burns, incisions, ulcers, for treating osteoporosis,

CC bone degenerative disorders, or periodontal disease, and for gut

CC protection or regeneration and treatment of lung or liver fibrosis,

CC reperfusion injury in various tissues and conditions resulting from

CC systemic cytokine damage.

CC N.B. The sequence data for this patent did not form part of the printed

CC specification, but was obtained in electronic format directly from WIPO

CC at [ftp.wipo.int/pub/published\\_pct\\_sequences](http://wipo.int/pub/published_pct_sequences).

XX

Sequence 57 AA;

Query Match 11.1%; Score 9; DB 23; Length 57;

Best Local Similarity 100.0%; Pred. No. 0.076;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 7 LEIYLFIYF 15

|||||||

Db 40 LEIYLFIYF 48

RESULT 11

AAB58270

ID AAB58270 standard; Protein: 77 AA.

XX

AC AAB58270;

XX

DT 14-MAR-2001 (first entry)

XX

DE Lung cancer associated polypeptide sequence SEQ ID 608.

XX

KM Human: lung cancer associated protein; neuroprotective; cyrostatic;

KM cardioactive; immunomodulatory; muscular active; vulnery;

KM gastrointestinal; nephrotoxic; antilinfective; gynecological;

KM antibacterial; diagnosis; neural disorder; immune disorder; reproductive;

KM proliferative disorder; wound healing; infectious disease.

XX

OS Homo sapiens.

XX

PN WO200055180-A2.

PD

XX 21-SEP-2000.

XX

PE 08-MAR-2000; 2000WO-US05918.

XX

PR 12-MAR-1999; 99US-0124270.

XX

PA (HUMA-) HUMAN GENOME SCI INC.

PA (ROSE/) ROSEN C A.

PI Ruben SM;

PI WPI: 2000-587514/55.

DR N-PSDB; AAF18146.

XX

PT Lung cancer associated gene sequences, referred to as lung cancer

PT antigens, useful for treatment, prevention, and diagnosis of disorders

PT such as lung cancer

XX

PS Claim 11; Page 1100; 1425pp; English.

XX

CC Polynucleotide sequences AAF17982 - AAF18424 encode human lung cancer

CC associated proteins represented in AAB58106 - AAB58548. Lung cancer

CC associated proteins and polynucleotide sequences, their agonists, and

CC antagonists may have neuroprotective; cyrostatic; cardioactive;

CC immunomodulatory; muscular active general; vulnery; gastrointestinal

CC general; nephrotoxic; antilinfective; gynecological; or antibacterial

CC activity. The invention also includes antibodies specific for the

CC protein or polynucleotide sequences. The lung cancer associated

CC polynucleotide sequences may be used for detection of lung cancer,

CC chromosome identification, as chromosome markers, and for numerous other

CC diagnostic or research purposes. The proteins may be used to treat

CC disorders such as neural, immune, muscular, reproductive,

CC gastrointestinal, pulmonary, cardiovascular, renal, and proliferative

CC disorders. The proteins may also be used in the treatment of wounds and

CC infectious diseases. Polynucleotide sequences AAF18425 - AAF18433 and

CC peptide AAB58549 are used in the course of the invention for the

CC identification and characterisation of the polynucleotide and protein

CC sequences.

XX

Sequence 77 AA;

SO

Query Match 11.1%; Score 9; DB 21; Length 77;

Best Local Similarity 100.0%; Pred. No. 0.098;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 6 HLFYLFYF 14  
 |||||  
 Db 13 HLFYLFYF 21

RESULT 12  
 AAO06842  
 ID AAO06842 standard; Protein: 82 AA.  
 XX  
 AC AAO06842;

DT 06-NOV-2001 (first entry)

DE Human polypeptide SEQ ID NO 20734.

XX Human; cytokine; cell proliferation; cell differentiation; gene therapy;  
 KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;  
 KW tissue growth factor; immunomodulatory; cancer; leukaemia;  
 KW nervous system disorders; arthritis; inflammation.

OS Homo sapiens.

PN WO200164835-A2.

PD 07-SEP-2001.

PE 26-FEB-2001; 2001WO-US04927.

XX 28-FEB-2000; 2000US-0515126.

PR 18-MAY-2000; 2000US-0577409.

PA (HYSE-) HYSEQ INC.

PI Tang YT, Liu C, Drmanac RT;

DR WPI; 2001-514838/56.

DR N-PSDB; AA186773.

PT Isolated nucleic acids and polypeptides, useful for preventing  
 PT diagnosing and treating e.g. leukaemia, inflammation and immune  
 PT disorders -

PS Claim 20; SEQ ID NO 20734; 1399pp + Sequence Listing; English.

CC The invention relates to human polynucleotides (AA179941-AA193841) and  
 CC the encoded proteins (AA000010-AA03910) that exhibit activity elating to  
 CC cytokine, cell proliferation or cell differentiation or which may induce  
 CC production of other cytokines in other cell populations. The  
 CC polynucleotides and polypeptides are useful in gene therapy, vaccines or  
 CC peptide therapy. The polypeptides have various cytokine-like activities,  
 CC e.g. stem cell growth factor activity, haematopoiesis regulating  
 CC activity, tissue growth factor activity, immunomodulatory activity and  
 CC activin/inhibin activity and may be useful in the diagnosis and/or  
 CC treatment of cancer, leukaemia, nervous system disorders, arthritis and  
 CC inflammation.  
 CC Note: The sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/published\_pct\_sequences.

XX Sequence 82 AA;

Query Match 11.1%; Score 9; DB 22; Length 82;

Best Local Similarity 100.0%; Pred. No. 0.1;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 YSLGDRARL 26  
 |||||  
 Db 38 YSLGDRARL 46

RESULT 13

AAO10269  
 ID AAO10269 standard; Protein: 88 AA.  
 XX  
 AC AAO10269;

DT 06-NOV-2001 (first entry)

DE Human polypeptide SEQ ID NO 24161.

XX Human; cytokine; cell proliferation; cell differentiation; gene therapy;  
 KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;  
 KW tissue growth factor; immunomodulatory; cancer; leukaemia;  
 KW nervous system disorders; arthritis; inflammation.

OS Homo sapiens.

PN WO200164835-A2.

PD 07-SEP-2001.

PE 26-FEB-2001; 2001WO-US04927.

XX 28-FEB-2000; 2000US-0515126.

PR 18-MAY-2000; 2000US-0577409.

PA (HYSE-) HYSEQ INC.

PI Tang YT, Liu C, Drmanac RT;

DR WPI; 2001-514838/56.

DR N-PSDB; AA190200.

PT Isolated nucleic acids and polypeptides, useful for preventing  
 PT diagnosing and treating e.g. leukaemia, inflammation and immune  
 PT disorders -

PS Claim 20; SEQ ID NO 24161; 1399pp + Sequence Listing; English.

CC The invention relates to human polynucleotides (AA179941-AA193841) and  
 CC the encoded proteins (AA000010-AA03910) that exhibit activity elating to  
 CC cytokine, cell proliferation or cell differentiation or which may induce  
 CC production of other cytokines in other cell populations. The  
 CC polynucleotides and polypeptides are useful in gene therapy, vaccines or  
 CC peptide therapy. The polypeptides have various cytokine-like activities,  
 CC e.g. stem cell growth factor activity, haematopoiesis regulating  
 CC activity, tissue growth factor activity, immunomodulatory activity and  
 CC activin/inhibin activity and may be useful in the diagnosis and/or  
 CC treatment of cancer, leukaemia, nervous system disorders, arthritis and  
 CC inflammation.  
 CC Note: The sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/published\_pct\_sequences.

XX Sequence 88 AA;

Query Match 11.1%; Score 9; DB 22; Length 88;

Best Local Similarity 100.0%; Pred. No. 0.11;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 7 LFIYLFYF 15  
 |||||  
 Db 41 LFIYLFYF 49

RESULT 14

ABG10494  
 ID ABG10494 standard; Protein: 115 AA.

XX ABG10494;

DT 13-FEB-2002 (first entry)

DE Novel human diagnostic protein #10485.



XX Human; chromosome mapping; gene mapping; gene therapy; forensic;  
 KW food supplement; medical imaging; diagnostic; genetic disorder.  
 XX Homo sapiens.  
 OS WO200175067-A2.  
 XX  
 XX 11-OCT-2001.  
 PD  
 XX  
 PF 30-MAR-2001; 2001WO-US08631.  
 XX  
 XX 31-MAR-2000; 2000US-0540217.  
 PR 23-AUG-2000; 2000US-0649167.  
 XX  
 PA (HYSE-) HYSEQ INC.  
 PL Dimaenac RT, Liu C, Tang YT;  
 PI  
 DR WPI; 2001-639362/73.  
 DR N-PSDB; AAS74681.  
 XX  
 PT New isolated polynucleotide and encoded polypeptides, useful in  
 PT diagnostics, forensics, gene mapping, identification of mutations  
 PT responsible for genetic disorders or other traits and to assess  
 PT biodiversity -  
 XX  
 PS Claim 20; SEQ ID No 40853; 103bp; English.  
 XX  
 CC The invention relates to isolated polynucleotide (I) and  
 CC polypeptide (II) sequences. (I) is useful as hybridisation probes,  
 CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome  
 CC and gene mapping, and in recombinant production of (II). The  
 CC polynucleotides are also used in diagnostics as expressed sequence tags  
 CC for identifying expressed genes. (I) is useful in gene therapy techniques  
 CC to restore normal activity of (II) or to treat disease states involving  
 CC (II). (II) is useful for generating antibodies against it, detecting or  
 CC quantitating a polypeptide in tissue, as molecular weight markers and as  
 CC a food supplement. (II) and its binding partners are useful in medical  
 CC imaging of sites expressing (II). (I) and (II) are useful for treating  
 CC disorders involving aberrant protein expression or biological activity.  
 CC The polypeptide and polynucleotide sequences have applications in  
 CC diagnostics, forensics, gene mapping, identification of mutations  
 CC responsible for genetic disorders or other traits to assess biodiversity  
 CC and to produce other types of data and products dependent on DNA and  
 CC amino acid sequences. ABG00010-ABG30377 represent novel human  
 CC diagnostic amino acid sequences of the invention.  
 CC Note: The sequence data for this patent did not appear in the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/published\_pcl\_sequences.  
 CC  
 XX  
 SQ Sequence 115 AA;  
 Query Match 11.1%; Score 9; DB 22; Length 115;  
 Best Local Similarity 100.0%; Pred. No. 0.14;  
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 OY 20 LGDRARLCL 28  
 Db 65 LGDRARLCL 73  
 RESULT 15  
 AAM96077  
 ID AAM96077 standard; Protein: 120 AA.  
 XX  
 AC AAM96077;  
 XX  
 DT 21-NOV-2001 (first entry)  
 DE Human reproductive system related antigen SEQ ID NO: 4735.  
 XX  
 KW Human; reproductive system related antigen; reproductive system disorder;

KW cancer; gene therapy.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO20015320-A2.  
 XX  
 PD 02-AUG-2001.  
 XX  
 PF 17-JAN-2001; 2001WO-US01339.  
 XX  
 XX 31-JAN-2000; 2000US-0179065.  
 PR 04-FEB-2000; 2000US-0180628.  
 PR 24-FEB-2000; 2000US-0184664.  
 PR 02-MAR-2000; 2000US-0186350.  
 PR 16-MAR-2000; 2000US-0189874.  
 PR 17-MAR-2000; 2000US-0190076.  
 PR 18-APR-2000; 2000US-0198123.  
 PR 19-MAY-2000; 2000US-0205515.  
 PR 07-JUN-2000; 2000US-0209467.  
 PR 28-JUN-2000; 2000US-0214886.  
 PR 30-JUN-2000; 2000US-0215135.  
 PR 07-JUL-2000; 2000US-0216647.  
 PR 07-JUL-2000; 2000US-0216880.  
 PR 11-JUL-2000; 2000US-0217487.  
 PR 14-JUL-2000; 2000US-0217496.  
 PR 14-JUL-2000; 2000US-0218290.  
 PR 26-JUL-2000; 2000US-0220963.  
 PR 26-JUL-2000; 2000US-0220964.  
 PR 14-AUG-2000; 2000US-0224518.  
 PR 14-AUG-2000; 2000US-0224519.  
 PR 14-AUG-2000; 2000US-0225213.  
 PR 14-AUG-2000; 2000US-0225214.  
 PR 14-AUG-2000; 2000US-0225266.  
 PR 14-AUG-2000; 2000US-0225267.  
 PR 14-AUG-2000; 2000US-0225268.  
 PR 14-AUG-2000; 2000US-0225270.  
 PR 14-AUG-2000; 2000US-0225447.  
 PR 14-AUG-2000; 2000US-0225757.  
 PR 14-AUG-2000; 2000US-0225758.  
 PR 14-AUG-2000; 2000US-0225759.  
 PR 18-AUG-2000; 2000US-0226279.  
 PR 22-AUG-2000; 2000US-0226681.  
 PR 22-AUG-2000; 2000US-0226868.  
 PR 22-AUG-2000; 2000US-0227182.  
 PR 23-AUG-2000; 2000US-0227009.  
 PR 30-AUG-2000; 2000US-0228924.  
 PR 01-SEP-2000; 2000US-0229287.  
 PR 01-SEP-2000; 2000US-0229343.  
 PR 01-SEP-2000; 2000US-0229344.  
 PR 01-SEP-2000; 2000US-0229345.  
 PR 05-SEP-2000; 2000US-0229509.  
 PR 05-SEP-2000; 2000US-0229513.  
 PR 06-SEP-2000; 2000US-0230437.  
 PR 06-SEP-2000; 2000US-0230438.  
 PR 08-SEP-2000; 2000US-0231242.  
 PR 08-SEP-2000; 2000US-0231243.  
 PR 08-SEP-2000; 2000US-0231244.  
 PR 08-SEP-2000; 2000US-0231413.  
 PR 08-SEP-2000; 2000US-0231414.  
 PR 08-SEP-2000; 2000US-0232080.  
 PR 08-SEP-2000; 2000US-0232081.  
 PR 12-SEP-2000; 2000US-0231968.  
 PR 14-SEP-2000; 2000US-0232397.  
 PR 14-SEP-2000; 2000US-0232398.  
 PR 14-SEP-2000; 2000US-0232399.  
 PR 14-SEP-2000; 2000US-0232400.  
 PR 14-SEP-2000; 2000US-0232401.  
 PR 14-SEP-2000; 2000US-0233063.  
 PR 14-SEP-2000; 2000US-0233064.  
 PR 14-SEP-2000; 2000US-0233065.  
 PR 21-SEP-2000; 2000US-0234223.  
 PR 21-SEP-2000; 2000US-0234274.  
 PR 25-SEP-2000; 2000US-0234997.

PR 25-SEP-2000; 2000US-0234998.  
PR 26-SEP-2000; 2000US-0235484.  
PR 27-SEP-2000; 2000US-0235834.  
PR 27-SEP-2000; 2000US-0235836.  
PR 29-SEP-2000; 2000US-0236327.  
PR 29-SEP-2000; 2000US-0236367.  
PR 29-SEP-2000; 2000US-0236368.  
PR 29-SEP-2000; 2000US-0236369.  
PR 29-SEP-2000; 2000US-0236370.  
PR 02-OCT-2000; 2000US-0236802.  
PR 02-OCT-2000; 2000US-0237037.  
PR 02-OCT-2000; 2000US-0237038.  
PR 02-OCT-2000; 2000US-0237039.  
PR 02-OCT-2000; 2000US-0237040.  
PR 13-OCT-2000; 2000US-0239935.  
PR 13-OCT-2000; 2000US-0239937.  
PR 20-OCT-2000; 2000US-0240960.  
PR 20-OCT-2000; 2000US-0241221.  
PR 20-OCT-2000; 2000US-0241785.  
PR 20-OCT-2000; 2000US-0241786.  
PR 20-OCT-2000; 2000US-0241787.  
PR 20-OCT-2000; 2000US-0241808.  
PR 20-OCT-2000; 2000US-0241809.  
PR 20-OCT-2000; 2000US-0241826.  
PR 01-NOV-2000; 2000US-0244617.  
PR 08-NOV-2000; 2000US-0246474.  
PR 08-NOV-2000; 2000US-0246475.  
PR 08-NOV-2000; 2000US-0246476.  
PR 08-NOV-2000; 2000US-0246477.  
PR 08-NOV-2000; 2000US-0246478.  
PR 08-NOV-2000; 2000US-0246523.  
PR 08-NOV-2000; 2000US-0246524.  
PR 08-NOV-2000; 2000US-0246525.  
PR 08-NOV-2000; 2000US-0246526.  
PR 08-NOV-2000; 2000US-0246527.  
PR 08-NOV-2000; 2000US-0246528.  
PR 08-NOV-2000; 2000US-0246532.  
PR 08-NOV-2000; 2000US-0246609.  
PR 08-NOV-2000; 2000US-0246610.  
PR 08-NOV-2000; 2000US-0246611.  
PR 08-NOV-2000; 2000US-0246613.  
PR 17-NOV-2000; 2000US-0249207.  
PR 17-NOV-2000; 2000US-0249208.  
PR 17-NOV-2000; 2000US-0249209.  
PR 17-NOV-2000; 2000US-0249210.  
PR 17-NOV-2000; 2000US-0249211.  
PR 17-NOV-2000; 2000US-0249212.  
PR 17-NOV-2000; 2000US-0249213.  
PR 17-NOV-2000; 2000US-0249214.  
PR 17-NOV-2000; 2000US-0249215.  
PR 17-NOV-2000; 2000US-0249216.  
PR 17-NOV-2000; 2000US-0249217.  
PR 17-NOV-2000; 2000US-0249218.  
PR 17-NOV-2000; 2000US-0249244.  
PR 17-NOV-2000; 2000US-0249245.  
PR 17-NOV-2000; 2000US-0249264.  
PR 17-NOV-2000; 2000US-0249265.  
PR 17-NOV-2000; 2000US-0249297.  
PR 17-NOV-2000; 2000US-0249299.  
PR 17-NOV-2000; 2000US-0249300.  
PR 01-DEC-2000; 2000US-0250160.  
PR 01-DEC-2000; 2000US-0250391.  
PR 05-DEC-2000; 2000US-0251030.  
PR 05-DEC-2000; 2000US-0251988.  
PR 05-DEC-2000; 2000US-0256719.  
PR 06-DEC-2000; 2000US-0251479.  
PR 08-DEC-2000; 2000US-0251856.  
PR 08-DEC-2000; 2000US-0251868.  
PR 08-DEC-2000; 2000US-0251869.  
PR 08-DEC-2000; 2000US-0251989.  
PR 08-DEC-2000; 2000US-0251990.  
PR 11-DEC-2000; 2000US-0254097.  
PR 05-JAN-2001; 2001US-0259678.

XX  
PA (HUMA-) HUMAN GENOME SCI INC.  
XX  
PI Rosen CA, Barash SC, Ruben SM;  
XX  
DR WPI; 2001-465570/50.  
DR N-PSDB; AAL02047.  
XX  
PT Isolated nucleic acid molecule encoding a reproductive system antigen  
PT is used in preventing, treating or ameliorating a medical condition  
XX  
PS Claim 11; SEQ ID NO 4735; 1297pp + Sequence listing; English.  
XX  
CC The present invention provides the protein and coding sequences of a  
CC number of human reproductive system related antigens. These can be used  
CC in the prevention and treatment of reproductive system disorders,  
CC including cancer. The present sequence is a protein of the invention.  
XX  
SQ Sequence 120 AA;

Query Match 11.1%; Score 9; DB 22; Length 120;  
Best Local Similarity 100.0%; Pred. No. 0.14; Mismatches 0; Gaps 0;  
Matches 9; Conservative 0; Indels 0; Gaps 0;  
QY 20 LGDRARLCL 28  
|||||||  
DB 30 LGDRARLCL 38

Search completed: May 29, 2003, 15:30:40  
Job time : 71 secs